Role of the Osteocyte in Musculoskeletal Disease.
Cachexia
DMD
Muscle atrophy
Osteocytes
Sarcopenia
Journal
Current osteoporosis reports
ISSN: 1544-2241
Titre abrégé: Curr Osteoporos Rep
Pays: United States
ID NLM: 101176492
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
accepted:
12
04
2023
medline:
11
5
2023
pubmed:
21
4
2023
entrez:
21
04
2023
Statut:
ppublish
Résumé
The purpose of this review is to summarize the role of the osteocyte in muscle atrophy in cancer patients, sarcopenia, spinal cord injury, Duchenne's muscular dystrophy, and other conditions associated with muscle deterioration. One type of bone cell, the osteocyte, appears to play a major role in muscle and bone crosstalk, whether physiological or pathological. Osteocytes are cells living within the bone-mineralized matrix. These cells are connected to each other by means of dendrites to create an intricately connected network. The osteocyte network has been shown to respond to different types of stimuli such as mechanical unloading, immobilization, aging, and cancer by producing osteocytes-derived factors. It is now becoming clear that some of these factors including sclerostin, RANKL, TGF-β, and TNF-α have detrimental effects on skeletal muscle. Bone and muscle not only communicate mechanically but also biochemically. Osteocyte-derived factors appear to contribute to the pathogenesis of muscle disease and could be used as a cellular target for new therapeutic approaches.
Identifiants
pubmed: 37084017
doi: 10.1007/s11914-023-00788-5
pii: 10.1007/s11914-023-00788-5
doi:
Substances chimiques
Transforming Growth Factor beta
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
303-310Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Bonewald L. Use it or lose it to age: a review of bone and muscle communication. Bone. 2019;120:212–8. https://doi.org/10.1016/j.bone.2018.11.002 .
doi: 10.1016/j.bone.2018.11.002
pubmed: 30408611
Rosenberg N, Rosenberg O, Soudry M. Osteoblasts in bone physiology-mini review. Rambam Maimonides Med J. 2012;3(2):e0013. https://doi.org/10.5041/RMMJ.10080 .
Feng X, Teitelbaum SL. Osteoclasts: new Insights. Bone Res. 2013;1(1):11–26. https://doi.org/10.4248/BR201301003 .
doi: 10.4248/BR201301003
pubmed: 26273491
Bonewald LF. The amazing osteocyte. J Bone Miner Res. 2011;26(2):229–38. https://doi.org/10.1002/jbmr.320 .
doi: 10.1002/jbmr.320
pubmed: 21254230
Robling AG, Bonewald LF. The osteocyte: new insights. Annu Rev Physiol. 2020;82:485–506. https://doi.org/10.1146/annurev-physiol-021119-034332 .
doi: 10.1146/annurev-physiol-021119-034332
pubmed: 32040934
pmcid: 8274561
Siller-Jackson AJ, Burra S, Gu S, Xia X, Bonewald LF, Sprague E, et al. Adaptation of connexin 43-hemichannel prostaglandin release to mechanical loading. J Biol Chem. 2008;283(39):26374–82. https://doi.org/10.1074/jbc.M803136200 .
doi: 10.1074/jbc.M803136200
pubmed: 18676366
pmcid: 2546557
Yoshimoto T, Kittaka M, Doan AAP, Urata R, Prideaux M, Rojas RE, et al. Osteocytes directly regulate osteolysis via MYD88 signaling in bacterial bone infection. Nat Commun. 2022;13(1):6648. https://doi.org/10.1038/s41467-022-34352-z .
doi: 10.1038/s41467-022-34352-z
pubmed: 36333322
pmcid: 9636212
Xiong J, Piemontese M, Onal M, Campbell J, Goellner JJ, Dusevich V, et al. Osteocytes, not osteoblasts or lining cells, are the main source of the rankl required for osteoclast formation in remodeling bone. PLoS One. 2015;10(9):e0138189. https://doi.org/10.1371/journal.pone.0138189 .
Ono T, Hayashi M, Sasaki F, Nakashima T. RANKL biology: bone metabolism, the immune system, and beyond. Inflamm Regen. 2020;40:2. https://doi.org/10.1186/s41232-019-0111-3 .
doi: 10.1186/s41232-019-0111-3
pubmed: 32047573
pmcid: 7006158
Xiong J, O’Brien CA. Osteocyte RANKL: new insights into the control of bone remodeling. J Bone Miner Res. 2012;27(3):499–505. https://doi.org/10.1002/jbmr.1547 .
doi: 10.1002/jbmr.1547
pubmed: 22354849
O’Brien W, Fissel BM, Maeda Y, Yan J, Ge X, Gravallese EM, et al. RANK-independent osteoclast formation and bone erosion in inflammatory arthritis. Arthritis Rheumatol. 2016;68(12):2889–900. https://doi.org/10.1002/art.39837 .
doi: 10.1002/art.39837
pubmed: 27563728
pmcid: 5125876
Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005;19(13):1842–4. https://doi.org/10.1096/fj.05-4221fje .
doi: 10.1096/fj.05-4221fje
pubmed: 16123173
Wang JS, Mazur CM, Wein MN. Sclerostin and osteocalcin: candidate bone-produced hormones. Front Endocrinol (Lausanne). 2021;12:584147. https://doi.org/10.3389/fendo.2021.584147 .
Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem. 2008;283(9):5866–75. https://doi.org/10.1074/jbc.M705092200 .
doi: 10.1074/jbc.M705092200
pubmed: 18089564
Huang J, Romero-Suarez S, Lara N, Mo C, Kaja S, Brotto L, et al. Crosstalk between MLO-Y4 osteocytes and C2C12 muscle cells is mediated by the Wnt/beta-catenin pathway. JBMR Plus. 2017;1(2):86–100. https://doi.org/10.1002/jbm4.10015 .
doi: 10.1002/jbm4.10015
pubmed: 29104955
pmcid: 5667655
Tsourdi E, Jahn K, Rauner M, Busse B, Bonewald LF. Physiological and pathological osteocytic osteolysis. J Musculoskelet Neuronal Interact. 2018;18(3):292–303.
pubmed: 30179206
pmcid: 6146198
Parfitt AM. The cellular basis of bone turnover and bone loss: a rebuttal of the osteocytic resorption–bone flow theory. Clin Orthop Relat Res. 1977;127:236–47.
van der Plas A, Aarden EM, Feijen JH, de Boer AH, Wiltink A, Alblas MJ, et al. Characteristics and properties of osteocytes in culture. J Bone Miner Res. 1994;9(11):1697–704. https://doi.org/10.1002/jbmr.5650091105 .
doi: 10.1002/jbmr.5650091105
pubmed: 7863820
Qing H, Ardeshirpour L, Pajevic PD, Dusevich V, Jahn K, Kato S, et al. Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation. J Bone Miner Res. 2012;27(5):1018–29. https://doi.org/10.1002/jbmr.1567 .
doi: 10.1002/jbmr.1567
pubmed: 22308018
Jahn K, Kelkar S, Zhao H, Xie Y, Tiede-Lewis LM, Dusevich V, et al. Osteocytes acidify their microenvironment in response to PTHrP in vitro and in lactating mice in vivo. J Bone Miner Res. 2017;32(8):1761–72. https://doi.org/10.1002/jbmr.3167 .
doi: 10.1002/jbmr.3167
pubmed: 28470757
Yamazaki M, Michigami T. Osteocytes and the pathogenesis of hypophosphatemic rickets. Front Endocrinol (Lausanne). 2022;13:1005189. https://doi.org/10.3389/fendo.2022.1005189 .
doi: 10.3389/fendo.2022.1005189
pubmed: 36246908
Qing H, Bonewald LF. Osteocyte remodeling of the perilacunar and pericanalicular matrix. Int J Oral Sci. 2009;1(2):59–65. https://doi.org/10.4248/ijos.09019 .
doi: 10.4248/ijos.09019
pubmed: 20687297
pmcid: 3470108
Youlten SE, Kemp JP, Logan JG, Ghirardello EJ, Sergio CM, Dack MRG, et al. Osteocyte transcriptome mapping identifies a molecular landscape controlling skeletal homeostasis and susceptibility to skeletal disease. Nat Commun. 2021;12(1):2444. https://doi.org/10.1038/s41467-021-22517-1 .
doi: 10.1038/s41467-021-22517-1
pubmed: 33953184
pmcid: 8100170
Mo C, Zhao R, Vallejo J, Igwe O, Bonewald L, Wetmore L, et al. Prostaglandin E2 promotes proliferation of skeletal muscle myoblasts via EP4 receptor activation. Cell Cycle. 2015;14(10):1507–16. https://doi.org/10.1080/15384101.2015.1026520 .
doi: 10.1080/15384101.2015.1026520
pubmed: 25785867
pmcid: 4615122
Palla AR, Ravichandran M, Wang YX, Alexandrova L, Yang AV, Kraft P, et al. Inhibition of prostaglandin-degrading enzyme 15-PGDH rejuvenates aged muscle mass and strength. Science. 2021;371(6528). https://doi.org/10.1126/science.abc8059 .
Jurimae J, Karvelyte V, Remmel L, Tamm AL, Purge P, Gruodyte-Raciene R, et al. Serum sclerostin concentration is associated with specific adipose, muscle and bone tissue markers in lean adolescent females with increased physical activity. J Pediatr Endocrinol Metab. 2021;34(6):755–61. https://doi.org/10.1515/jpem-2020-0662 .
doi: 10.1515/jpem-2020-0662
pubmed: 33851796
Kim JA, Roh E, Hong SH, Lee YB, Kim NH, Yoo HJ, et al. Association of serum sclerostin levels with low skeletal muscle mass: The Korean Sarcopenic Obesity Study (KSOS). Bone. 2019;128:115053. https://doi.org/10.1016/j.bone.2019.115053 .
Wood CL, Pajevic PD, Gooi JH. Osteocyte secreted factors inhibit skeletal muscle differentiation. Bone Rep. 2017;6:74–80. https://doi.org/10.1016/j.bonr.2017.02.007 .
doi: 10.1016/j.bonr.2017.02.007
pubmed: 28377986
pmcid: 5365311
Traub J, Bergheim I, Eibisberger M, Stadlbauer V. Sarcopenia and liver cirrhosis-comparison of the European Working Group on Sarcopenia Criteria 2010 and 2019. Nutrients. 2020;12(2). https://doi.org/10.3390/nu12020547 .
Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol. 2018;14(9):513–37. https://doi.org/10.1038/s41574-018-0062-9 .
doi: 10.1038/s41574-018-0062-9
pubmed: 30065268
pmcid: 6241236
Keramidaki K, Tsagari A, Hiona M, Risvas G. Osteosarcopenic obesity, the coexistence of osteoporosis, sarcopenia and obesity and consequences in the quality of life in older adults >/=65 years-old in Greece. J Frailty Sarcopenia Falls. 2019;4(4):91–101. https://doi.org/10.22540/JFSF-04-091 .
Busse B, Djonic D, Milovanovic P, Hahn M, Puschel K, Ritchie RO, et al. Decrease in the osteocyte lacunar density accompanied by hypermineralized lacunar occlusion reveals failure and delay of remodeling in aged human bone. Aging Cell. 2010;9(6):1065–75. https://doi.org/10.1111/j.1474-9726.2010.00633.x .
doi: 10.1111/j.1474-9726.2010.00633.x
pubmed: 20874757
D’Angelo MA, Raices M, Panowski SH, Hetzer MW. Age-dependent deterioration of nuclear pore complexes causes a loss of nuclear integrity in postmitotic cells. Cell. 2009;136(2):284–95. https://doi.org/10.1016/j.cell.2008.11.037 .
doi: 10.1016/j.cell.2008.11.037
pubmed: 19167330
pmcid: 2805151
Modder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 2011;26(2):373–9. https://doi.org/10.1002/jbmr.217 .
doi: 10.1002/jbmr.217
pubmed: 20721932
Medeiros MC, Rocha N, Bandeira E, Dantas I, Chaves C, Oliveira M, et al. Serum sclerostin, body composition, and sarcopenia in hemodialysis patients with diabetes. Int J Nephrol. 2020;2020:4596920. https://doi.org/10.1155/2020/4596920 .
doi: 10.1155/2020/4596920
pubmed: 32095286
pmcid: 7035555
Ahn SH, Jung HW, Lee E, Baek JY, Jang IY, Park SJ, et al. Decreased serum level of sclerostin in older adults with sarcopenia. Endocrinol Metab (Seoul). 2022. https://doi.org/10.3803/EnM.2022.1428 .
doi: 10.3803/EnM.2022.1428
pubmed: 36604955
Kim SP, Frey JL, Li Z, Kushwaha P, Zoch ML, Tomlinson RE, et al. Sclerostin influences body composition by regulating catabolic and anabolic metabolism in adipocytes. Proc Natl Acad Sci U S A. 2017;114(52):E11238–47. https://doi.org/10.1073/pnas.1707876115 .
doi: 10.1073/pnas.1707876115
pubmed: 29229807
pmcid: 5748171
Dufresne SS, Dumont NA, Boulanger-Piette A, Fajardo VA, Gamu D, Kake-Guena SA, et al. Muscle RANK is a key regulator of Ca2+ storage, SERCA activity, and function of fast-twitch skeletal muscles. Am J Physiol Cell Physiol. 2016;310(8):C663–72. https://doi.org/10.1152/ajpcell.00285.2015 .
doi: 10.1152/ajpcell.00285.2015
pubmed: 26825123
pmcid: 4835920
Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest. 2003;111(8):1221–30. https://doi.org/10.1172/JCI17215 .
doi: 10.1172/JCI17215
pubmed: 12697741
pmcid: 152939
Bonnet N, Bourgoin L, Biver E, Douni E, Ferrari S. RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. J Clin Invest. 2019;129(8):3214–23. https://doi.org/10.1172/JCI125915 .
doi: 10.1172/JCI125915
pubmed: 31120440
pmcid: 6668701
Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95. https://doi.org/10.1016/S1470-2045(10)70218-7 .
doi: 10.1016/S1470-2045(10)70218-7
pubmed: 21296615
von Haehling S, Anker SD. Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014. J Cachexia Sarcopenia Muscle. 2014;5(4):261–3. https://doi.org/10.1007/s13539-014-0164-8 .
doi: 10.1007/s13539-014-0164-8
Pourquie O. Vertebrate somitogenesis. Annu Rev Cell Dev Biol. 2001;17:311–50. https://doi.org/10.1146/annurev.cellbio.17.1.311 .
doi: 10.1146/annurev.cellbio.17.1.311
pubmed: 11687492
Waning DL, Mohammad KS, Reiken S, Xie W, Andersson DC, John S, et al. Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nat Med. 2015;21(11):1262–71. https://doi.org/10.1038/nm.3961 .
doi: 10.1038/nm.3961
pubmed: 26457758
pmcid: 4636436
Hesse E, Schröder S, Brandt D, Pamperin J, Saito H, Taipaleenmäki H. Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness. JCI Insight. 2019;5(9):e125543. https://doi.org/10.1172/jci.insight.125543 .
Narasimhan A, Shahda S, Kays JK, Perkins SM, Cheng L, Schloss KNH, et al. Identification of potential serum protein biomarkers and pathways for pancreatic cancer cachexia using an aptamer-based discovery platform. Cancers (Basel). 2020;12(12):3787. https://doi.org/10.3390/cancers12123787 .
Bonetto A, Kays JK, Parker VA, Matthews RR, Barreto R, Puppa MJ, et al. Differential bone loss in mouse models of colon cancer cachexia. Front Physiol. 2016;7:679. https://doi.org/10.3389/fphys.2016.00679 .
doi: 10.3389/fphys.2016.00679
pubmed: 28123369
Huot JR, Novinger LJ, Pin F, Narasimhan A, Zimmers TA, O’Connell TM, et al. Formation of colorectal liver metastases induces musculoskeletal and metabolic abnormalities consistent with exacerbated cachexia. JCI Insight. 2020;5(9):e136687. https://doi.org/10.1172/jci.insight.136687 .
Huot JR, Pin F, Essex AL, Bonetto A. MC38 tumors induce musculoskeletal defects in colorectal cancer. Int J Mol Sci. 2021;22(3):1486. https://doi.org/10.3390/ijms22031486 .
Berent TE, Dorschner JM, Craig TA, Drake MT, Westendorf JJ, Kumar R. Lung tumor cells inhibit bone mineralization and osteoblast activity. Biochem Biophys Res Commun. 2019;519(3):566–71. https://doi.org/10.1016/j.bbrc.2019.09.045 .
doi: 10.1016/j.bbrc.2019.09.045
pubmed: 31537378
pmcid: 6879054
Pin F, Barreto R, Kitase Y, Mitra S, Erne CE, Novinger LJ, et al. Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia. J Cachexia Sarcopenia Muscle. 2018;9(4):685–700. https://doi.org/10.1002/jcsm.12311 .
doi: 10.1002/jcsm.12311
pubmed: 30009406
pmcid: 6104117
Pin F, Prideaux M, Huot JR, Essex AL, Plotkin LI, Bonetto A, et al. Non-bone metastatic cancers promote osteocyte-induced bone destruction. Cancer Lett. 2021;520:80–90. https://doi.org/10.1016/j.canlet.2021.06.030 .
doi: 10.1016/j.canlet.2021.06.030
pubmed: 34233150
pmcid: 8440379
Pin F, Jones AJ, Huot JR, Narasimhan A, Zimmers TA, Bonewald LF, et al. RANKL blockade reduces cachexia and bone loss induced by non-metastatic ovarian cancer in mice. J Bone Miner Res. 2022;37(3):381–96. https://doi.org/10.1002/jbmr.4480 .
doi: 10.1002/jbmr.4480
pubmed: 34904285
Wang H, Xia Y, Li B, Li Y, Fu C. Reverse adverse immune microenvironments by biomaterials enhance the repair of spinal cord injury. Front Bioeng Biotechnol. 2022;10:812340. https://doi.org/10.3389/fbioe.2022.812340 .
Giangregorio L, McCartney N. Bone loss and muscle atrophy in spinal cord injury: epidemiology, fracture prediction, and rehabilitation strategies. J Spinal Cord Med. 2006;29(5):489–500. https://doi.org/10.1080/10790268.2006.11753898 .
doi: 10.1080/10790268.2006.11753898
pubmed: 17274487
pmcid: 1949032
Invernizzi M, Carda S, Rizzi M, Grana E, Squarzanti DF, Cisari C, et al. Evaluation of serum myostatin and sclerostin levels in chronic spinal cord injured patients. Spinal Cord. 2015;53(8):615–20. https://doi.org/10.1038/sc.2015.61 .
doi: 10.1038/sc.2015.61
pubmed: 25896346
Maimoun L, Ben Bouallegue F, Gelis A, Aouinti S, Mura T, Philibert P, et al. Periostin and sclerostin levels in individuals with spinal cord injury and their relationship with bone mass, bone turnover, fracture and osteoporosis status. Bone. 2019;127:612–9. https://doi.org/10.1016/j.bone.2019.07.019 .
doi: 10.1016/j.bone.2019.07.019
pubmed: 31351195
Qin W, Li X, Peng Y, Harlow LM, Ren Y, Wu Y, et al. Sclerostin antibody preserves the morphology and structure of osteocytes and blocks the severe skeletal deterioration after motor-complete spinal cord injury in rats. J Bone Miner Res. 2015;30(11):1994–2004. https://doi.org/10.1002/jbmr.2549 .
doi: 10.1002/jbmr.2549
pubmed: 25974843
Zhao W, Li X, Peng Y, Qin Y, Pan J, Li J, et al. Sclerostin antibody reverses the severe sublesional bone loss in rats after chronic spinal cord injury. Calcif Tissue Int. 2018;103(4):443–54. https://doi.org/10.1007/s00223-018-0439-8 .
doi: 10.1007/s00223-018-0439-8
pubmed: 29931461
pmcid: 7891854
Phillips EG, Beggs LA, Ye F, Conover CF, Beck DT, Otzel DM, et al. Effects of pharmacologic sclerostin inhibition or testosterone administration on soleus muscle atrophy in rodents after spinal cord injury. PLoS ONE. 2018;13(3):e0194440. https://doi.org/10.1371/journal.pone.0194440 .
Yiu EM, Kornberg AJ. Duchenne muscular dystrophy. J Paediatr Child Health. 2015;51(8):759–64. https://doi.org/10.1111/jpc.12868 .
doi: 10.1111/jpc.12868
pubmed: 25752877
Buckner JL, Bowden SA, Mahan JD. Optimizing bone health in duchenne muscular dystrophy. Int J Endocrinol. 2015;2015:928385. https://doi.org/10.1155/2015/928385 .
Gao X, Tang Y, Amra S, Sun X, Cui Y, Cheng H, et al. Systemic investigation of bone and muscle abnormalities in dystrophin/utrophin double knockout mice during postnatal development and the mechanisms. Hum Mol Genet. 2019;28(10):1738–51. https://doi.org/10.1093/hmg/ddz012 .
doi: 10.1093/hmg/ddz012
pubmed: 30689868
pmcid: 7275811
Dufresne SS, Boulanger-Piette A, Bosse S, Argaw A, Hamoudi D, Marcadet L, et al. Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy. Acta Neuropathol Commun. 2018;6(1):31. https://doi.org/10.1186/s40478-018-0533-1 .
doi: 10.1186/s40478-018-0533-1
pubmed: 29699580
pmcid: 5922009
Hamoudi D, Marcadet L, Piette Boulanger A, Yagita H, Bouredji Z, Argaw A, et al. An anti-RANKL treatment reduces muscle inflammation and dysfunction and strengthens bone in dystrophic mice. Hum Mol Genet. 2019;28(18):3101–12. https://doi.org/10.1093/hmg/ddz124 .
doi: 10.1093/hmg/ddz124
pubmed: 31179501
Akhtar Ali S, Kang H, Olney R, Ramos-Platt L, Ryabets-Lienhard A, Cheung C, et al. Evaluating RANKL and OPG levels in patients with Duchenne muscular dystrophy. Osteoporos Int. 2019;30(11):2283–8. https://doi.org/10.1007/s00198-019-05077-5 .
doi: 10.1007/s00198-019-05077-5
pubmed: 31392399
Belavy DL, Baecker N, Armbrecht G, Beller G, Buehlmeier J, Frings-Meuthen P, et al. Serum sclerostin and DKK1 in relation to exercise against bone loss in experimental bed rest. J Bone Miner Metab. 2016;34(3):354–65. https://doi.org/10.1007/s00774-015-0681-3 .
doi: 10.1007/s00774-015-0681-3
pubmed: 26056021
Frings-Meuthen P, Boehme G, Liphardt AM, Baecker N, Heer M, Rittweger J. Sclerostin and DKK1 levels during 14 and 21 days of bed rest in healthy young men. J Musculoskelet Neuronal Interact. 2013;13(1):45–52.
pubmed: 23445914
Spatz JM, Fields EE, Yu EW, Divieti Pajevic P, Bouxsein ML, Sibonga JD, et al. Serum sclerostin increases in healthy adult men during bed rest. J Clin Endocrinol Metab. 2012;97(9):E1736–40. https://doi.org/10.1210/jc.2012-1579 .
doi: 10.1210/jc.2012-1579
pubmed: 22767636
pmcid: 3431567
Brent MB, Bruel A, Thomsen JS. Anti-sclerostin antibodies and abaloparatide have additive effects when used as a countermeasure against disuse osteopenia in female rats. Bone. 2022;160:116417. https://doi.org/10.1016/j.bone.2022.116417 .
Speacht TL, Lang CH, Donahue HJ. Soluble RANKL exaggerates hindlimb suspension-induced osteopenia but not muscle protein balance. J Orthop Res. 2021;39(9):1860–9. https://doi.org/10.1002/jor.24917 .
doi: 10.1002/jor.24917
pubmed: 33222219